Tarsus Pharmaceuticals, Inc. SEC Filings

Welcome to our dedicated page for Tarsus Pharmaceuticals SEC filings (Ticker: TARS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Struggling to trace how FDA milestones, trial costs, and insider sales shape Tarsus Pharmaceuticals (TARS) prospects? Biotech filings run hundreds of pages, packed with clinical jargon about XDEMVY, TP-04, and TP-05. Missing a single risk factor in the annual report could skew your valuation.

Stock Titan solves that problem by pairing real-time EDGAR feeds with AI-powered summaries. Whether you need the Tarsus Pharmaceuticals quarterly earnings report 10-Q filing or a quick take on an 8-K announcing pivotal trial results, our platform highlights cash runway, trial endpoints, and revenue clues in plain language. Wondering about Tarsus Pharmaceuticals insider trading Form 4 transactions? Get instant alerts the moment executives buy or sell shares.

Here’s what you can uncover in seconds:

• Tarsus Pharmaceuticals annual report 10-K simplified – find R&D spend, patent timelines, and Demodex market sizing.
• Tarsus Pharmaceuticals Form 4 insider transactions real-time – monitor executive stock moves around FDA approvals.
• Tarsus Pharmaceuticals proxy statement executive compensation – see how milestone payouts align with shareholder value.
• Tarsus Pharmaceuticals 8-K material events explained – track trial readouts and licensing deals without wading through legalese.

Investors use these insights to compare quarter-over-quarter burn rates, gauge pipeline momentum, and spot early red flags. Understanding Tarsus Pharmaceuticals SEC documents with AI means faster, better-informed decisions—no medical dictionary required.